Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zymfentra Maintenance in Crohn's Disease (LIBERTY-CD)
NCT03945019Phase 3Completed
- Sponsor
- Celltrion
- Start
- Oct 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of infliximab in Crohn's disease, sponsored by Celltrion. Started Oct 2019; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03945019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945019.